

Eurofins Agro Testing supports CO₂ reduction with Soil Carbon Check offering

5 December 2022

To mark World Soil Day (December 5th), Eurofins Agro Testing announces the launch of Soil Carbon Check as part of Soil Health Solutions, a new suite of testing solutions that will support the agricultural sector to transition to more sustainable farming practices. The Soil Carbon Check test will provide insights into the levels of carbon storage in fields, which supports the reduction of CO₂ in the atmosphere. Through targeted soil management, farmers and growers can sequester increased levels of carbon and contribute to climate protection. Data garnered through the Soil Carbon Check test reports can be used to support sustainability claims and carbon credits, as proof of sustainable farming and as credentials for other partners in the agri-food chain.

The '4 per 1,000' initiative launched at the UN Climate Change Conference in Paris in 2015 (COP21) aims to boost carbon storage in agricultural soils by 0.4% each year to help mitigate climate change and increase food security. The amount of carbon that is stored in soil is as much as three times the amount of carbon sequestered by above-ground biomass (trees or other plants and crops). Increasing the amount of carbon stored in soil will contribute to the reduction of global warming; the more CO₂ stored in soil as organic carbon, the less CO₂ that is released into the atmosphere.

Soil Carbon Check provides customers with information on how much carbon is sequestered in their soil, how stable their soil carbon is and how it can be improved, and tracks how the carbon content of soil changes over time. In addition to Soil Carbon Check, the suite of tests offered by Soil Health Solutions provide insights into physical soil health (supporting the efficient use of water), potential contaminants in soil, biological soil health (to determine the biodiversity status of soil and effective actions to regenerate it) and chemical soil health (to prevent yield gaps and improve food quality). Further information is available [here](#).

Notes to Editors:

For more information, please visit www.eurofins.com or contact:

Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agrosience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000 staff across a decentralised and entrepreneurial network of 940 laboratories in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group's objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020 and 2021, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 40 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity.